IL6 and myeloid sarcoma: In summary, we postulated the following distinctive features of MS therapeutics correlating to NMOSD treatment failure: elevation of the total B cell count, memory B cells, immunoglobulins, plasmablasts, serum interleukin-6 and serum BAFF.